|
Oct 25
|
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
|
|
Oct 25
|
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
|
|
Oct 25
|
Trending tickers: Tesla, Lloyds, Capri, Deckers and Mercedes-Benz
|
|
Oct 24
|
How CIOs gain employee buy-in on generative AI
|
|
Oct 23
|
How The Oncology Sector Is Set To Fuel AstraZeneca’s (AZN) Growth
|
|
Oct 22
|
AstraZeneca Receives CHMP's Approval for Wainzua in Europe
|
|
Oct 22
|
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN
|
|
Oct 21
|
UK Stocks That May Be Trading Below Estimated Value
|
|
Oct 9
|
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Oct 8
|
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
|
|
Oct 8
|
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
|
|
Oct 8
|
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
|
|
Oct 8
|
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
|
|
Oct 7
|
5 Large Drug Stocks to Watch From a Thriving Industry
|
|
Oct 7
|
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
|
|
Oct 7
|
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
|
|
Oct 7
|
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
|
Oct 3
|
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
|
|
Oct 3
|
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
|
|
Oct 3
|
AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
|